Bioventus BVS U.S. Segment — Adjusted cost of sales
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bioventus in its filing.
Tagged under the XBRL concept bvs:AdjustedCostOfSales.
The official record: Bioventus’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bioventus's u.s. segment — adjusted cost of sales.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bioventus's U.S. segment — adjusted cost of sales?
- Bioventus (BVS) reported U.S. segment — adjusted cost of sales of $24.9M in Q1 2026.
- How has Bioventus's U.S. segment — adjusted cost of sales changed year-over-year?
- Bioventus's U.S. segment — adjusted cost of sales decreased by 2.0% year-over-year, from $25.4M to $24.9M.
- What is the long-term trend for Bioventus's U.S. segment — adjusted cost of sales?
- Over 3 years (2022 to 2025), Bioventus's U.S. segment — adjusted cost of sales has grown at a 1.2% compound annual growth rate (CAGR), from $109.96M to $113.82M.
- What does U.S. segment — adjusted cost of sales mean?
- This metric captures the direct costs associated with producing and delivering medical products sold within the U.S. segment, excluding non-recurring or non-operational charges. Monitoring this helps evaluate the efficiency of the supply chain and manufacturing processes for the domestic business.